| 3 | The genome sequence of star fruit(Averrhoa carambola)显示文摘Oxalidaceae is one of the most important plant families in horticulture,and its key commercially relevant genus,Averrhoa,has diverse growth habits and fruit types.Here,we describe the assembly of a high-quality chromosomescale genome sequence for Averrhoa carambola(star fruit).Ks distribution analysis showed that A.carambola underwent a whole-genome triplication event,i.e.,the gamma event shared by most eudicots.Comparisons between A.carambola and other angiosperms also permitted the generation of Oxalidaceae gene annotations.We identified unique gene families and analyzed gene family expansion and contraction.This analysis revealed significant changes in MADS-box gene family content,which might be related to the cauliflory of A.carambola.In addition,we identified and analyzed a total of 204 nucleotide-binding site,leucine-rich repeat receptor(NLR)genes and 58 WRKY genes in the genome,which may be related to the defense response.Our results provide insights into the origin,evolution and diversification of star fruit. | Shasha Wu Wei Sun Zhichao Xu Junwen Zhai Xiaoping Li Chengru Li Diyang Zhang Xiaoqian Wu Liming Shen Junhao Chen Hui Ren Xiaoyu Dai Zhongwu Dai Yamei Zhao Lei Chen Mengxia Cao Xinyu Xie Xuedie Liu Donghui Peng Jianwen Dong Yu-Yun Hsiao Shi-lin Chen Wen-Chieh Tsai Siren Lan Zhong-Jian Liu | 2020 | Horticulture Research2020，7，1： | 1 |
| 4 | Efficacy and safety of acupoint application for allergic rhinitis: a systematic review and Meta-analysis of randomized controlled trials显示文摘OBJECTIVE: To use evidence-based medicine to explore the efficacy of acupoint application(AA) for allergic rhinitis(AR) at different time points and its safety. METHODS: We searched 7 databases(Pub Med, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and China Biology Medicine disc) as well as the international clinical trial registration platform from January 2010 to March 2020 for randomized controlled trials(RCTs) comparing the efficacy of AA versus placebo, Western Medicine or other alternative therapies on AR. Risk of bias was assessed according to the Cochrane handbook, and statistical analysis was performed using Rev Man 5.3. Outcomes included the total effective rate, recurrence rate, total nasal symptom score(TNSS), visual analogue scale(VAS), quality of life measured by the Rhinitis Quality of Life Questionnaire(RQLQ) or Short Form-36(SF-36), adverse events, and biomarkers including immunoglobulin E(Ig E), peripheral blood eosinophil count(EOS), interleukin-4(IL-4), and interferon gamma(INF-γ). RESULTS: Twenty-eight RCTs involving 3282 participants were included. The short-term and long-term efficacy of AA was significantly better than placebo, including better total effective rate [RR: 3.05, 95%CI(1.84, 5.07), after treatment;RR: 9.29, 95%CI(2.57, 33.66), at 6 months], lower recurrence rate [RR: 0.55, 95%CI(0.45, 0.66), at 6 months;RR: 0.65, 95%CI(0.57, 0.74), at 1 year], lower TNSS [MD:-3.09, 95%CI(-3.58,-2.61), after treatment], and lower RQLQ [MD:-14.79, 95%CI(-21.49,-8.10), after treatment;MD:-11.92, 95%CI(-17.40,-6.45), at 4-6 months]. Compared with Western Medicine, AA had better long-term total effective rate [RR: 1.33, 95%CI(1.05, 1.69), at 3 months;RR: 1.49, 95%CI 1.22 to 1.81, at 1 year) and lower recurrence rate [RR: 0.48, 95%CI(0.39, 0.58), at 6 months;RR: 0.45, 95%CI(0.33, 0.60), at 1 year]. AA had better long-term total effective rate versus acupuncture [RR: 2.06, 95% CI(1.28, 3.31), at 1 year] or oral Chinese medicine [RR: 1.21, 95% CI(1.09, 1.34), ≥ 6 months]. Both AA and Western Medicine can reduce serum levels of Ig E, EOS, and IL-4 after treatment. The main adverse event of AA was local skin reaction without systemic side effects. CONCLUSIONS: The short-term(within one month) and long-term(at 3 months, 6 months and 1 year) efficacy of acupoint application on AR was better than that of placebo. The long-term efficacy of acupoint application was superior to that of Western Medicine(at 3 months, 6 months and 1 year), oral Chinese medicine(at more than 6 months) and acupuncture(at 1 year). AA can reduce serum Ig E, EOS, and IL-4 level of AR patients in a short run. Acupoint application is safe, but severe skin reactions can reduce patient compliance. | SHEN Mengxia SHANG Wenfang WU Jiangxia YU Zelin XUAN Lihua | 2022 | Journal of Traditional Chinese Medicine2022，42，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员